Royal Bank of Canada lessened its stake in Omnicell, Inc. (NASDAQ:OMCL) by 1.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 762,765 shares of the company’s stock after selling 12,083 shares during the period. Royal Bank of Canada’s holdings in Omnicell were worth $33,104,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Omnicell in the 1st quarter valued at about $116,000. Pitcairn Co. bought a new stake in shares of Omnicell in the 1st quarter valued at about $203,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Omnicell in the 1st quarter valued at about $223,000. Elkfork Partners LLC bought a new stake in shares of Omnicell in the 4th quarter valued at about $225,000. Finally, Jane Street Group LLC bought a new stake in shares of Omnicell in the 1st quarter valued at about $237,000. Hedge funds and other institutional investors own 98.79% of the company’s stock.
A number of equities research analysts have commented on OMCL shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $63.00 price target on shares of Omnicell in a research report on Tuesday, April 3rd. BidaskClub upgraded Omnicell from a “sell” rating to a “hold” rating in a research report on Saturday, April 7th. Finally, ValuEngine upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Wednesday, June 20th. Three analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $56.67.
Shares of Omnicell opened at $52.90 on Wednesday, MarketBeat reports. The stock has a market capitalization of $2.03 billion, a PE ratio of 98.68, a price-to-earnings-growth ratio of 2.41 and a beta of 0.78. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.22 and a current ratio of 1.68. Omnicell, Inc. has a 1 year low of $39.75 and a 1 year high of $55.40.
Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, April 26th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.04. The company had revenue of $182.60 million for the quarter, compared to the consensus estimate of $177.49 million. Omnicell had a return on equity of 4.11% and a net margin of 4.55%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 EPS. equities research analysts forecast that Omnicell, Inc. will post 1.38 EPS for the current fiscal year.
In other news, insider Robin Gene Seim sold 13,286 shares of the business’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $46.48, for a total value of $617,533.28. Following the transaction, the insider now directly owns 74,121 shares of the company’s stock, valued at approximately $3,445,144.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gary S. Petersmeyer sold 1,650 shares of the business’s stock in a transaction dated Thursday, May 17th. The shares were sold at an average price of $46.13, for a total value of $76,114.50. The disclosure for this sale can be found here. Insiders sold a total of 59,755 shares of company stock worth $2,840,350 over the last three months. 3.71% of the stock is owned by company insiders.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.